Merck & Co taps China's genomics expertise as it formalises alliance with BGI
This article was originally published in Scrip
Executive Summary
Merck & Co and the Chinese genomics company BGI have built on a statement of intent they signed around a year ago by entering into a formal collaboration to develop biomarkers and other genomic technologies with potential applications in drug discovery and diagnostics.